Professor of Surgery and Chief, Section of Surgical Endocrinology; Associate Director, Multidisciplinary Endocrine Center; and Fellowship Program Director of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Professor, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
CA Cancer J Clin. 2018 Jan;68(1):55-63. doi: 10.3322/caac.21439. Epub 2017 Nov 1.
Answer questions and earn CME/CNE This is a review of the major changes in the American Joint Committee on Cancer staging manual, eighth edition, for differentiated and anaplastic thyroid carcinoma. All patients younger than 55 years have stage I disease unless they have distant metastases, in which case, their disease is stage II. In patients aged 55 years or older, the presence of distant metastases confers stage IVB, while cases without distant metastases are further categorized based on the presence/absence of gross extrathyroidal extension, tumor size, and lymph node status. Patients aged 55 years or older whose tumor measures 4 cm or smaller (T1-T2) and is confined to the thyroid (N0, NX) have stage I disease, and those whose tumor measures greater than 4 cm and is confined to the thyroid (T3a) have stage II disease regardless of lymph node status. Patients aged 55 years or older whose tumor is confined to the thyroid and measures 4 cm or smaller (T1-T2) with any lymph node metastases present (N1a or N1b) have stage II disease. In patients who demonstrate gross extrathyroidal extension, the disease is considered stage II if only the strap muscles are grossly invaded (T3b); stage III if there is gross invasion of the subcutaneous tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve (T4a); or stage IVA if there is gross invasion of the prevertebral fascia or tumor encasing the carotid artery or internal jugular vein (T4b). The same T definitions will be used for both differentiated and anaplastic thyroid cancer, but the basic premise of the anatomic stage groups will remain the same. CA Cancer J Clin 2018;68:55-63. © 2017 American Cancer Society.
回答问题并获得 CME/CNE 学分 这是对第八版美国癌症联合委员会癌症分期手册中分化型和间变性甲状腺癌主要变化的综述。所有年龄小于 55 岁的患者均为 I 期疾病,除非有远处转移,在这种情况下,他们的疾病为 II 期。55 岁或以上的患者,存在远处转移则为 IVB 期,而无远处转移的病例则根据是否存在大体甲状腺外侵犯、肿瘤大小和淋巴结状态进一步分类。年龄 55 岁或以上的患者,肿瘤直径为 4cm 或更小(T1-T2)且局限于甲状腺(N0,NX)者为 I 期疾病,肿瘤直径大于 4cm 且局限于甲状腺(T3a)者无论淋巴结状态如何均为 II 期疾病。年龄 55 岁或以上的患者,肿瘤局限于甲状腺且直径为 4cm 或更小(T1-T2)且存在任何淋巴结转移(N1a 或 N1b)者为 II 期疾病。对于有大体甲状腺外侵犯的患者,如果仅被膜肌肉被侵犯(T3b)则疾病为 II 期;如果有皮下组织、喉、气管、食管或喉返神经侵犯(T4a)则为 III 期;如果有前纵膈筋膜或颈动脉或颈内静脉受侵犯(T4b)则为 IVA 期。分化型和间变性甲状腺癌将使用相同的 T 定义,但解剖分期组的基本前提仍保持不变。CA Cancer J Clin 2018;68:55-63. © 2017 美国癌症协会。